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Background: When used in general medical practices, buprenorphine is an effective treatment for opioid
dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care
in commercial health systems.
Methods: The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of
medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or
more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204)
over the time span 2007–2008 were included. Propensity scores were used to help adjust for group differences.
Results: Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs
than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578;
vs. mean health care costs with no addiction treatment = $31,055; p < .0001), while those receiving buprenorphine
plus addiction counseling and those with addiction counseling only did not differ significantly in total health care
costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus
counseling, those with little or no addiction treatment had significantly greater use of primary care (p < .001), other
medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with
buprenorphine plus counseling) used less inpatient detoxification (p < .001), and had significantly more PC visits
(p = .001), other medical visits (p = .005), and mental health visits (p = .002).
Conclusions: Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in
commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients
with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives.
Keywords: Substance abuse, Cost analysis, Health care utilization, Commercial health insurance, ParityBackground
Opioid abuse and dependence, whether through use of
heroin or prescription opioid medications, has high costs
to individuals, health care systems, and society. Total
costs, including health care, lost productivity, and costs of
crime, are more than $28 billion per year, with health care
alone costing over $8 billion [1,2]. Costs are increasing,
moreover, because of the increased prevalence of opioid
dependence [3,4] and its associated disease burdens (e.g.,* Correspondence: frances.lynch@kpchr.org
1Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue,
Portland, OR 97227, USA
Full list of author information is available at the end of the article
© 2014 Lynch et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orincreased risk of HIV, hepatitis C), as well as its emotional
and financial impacts on families [5,6].
Federal legislation permits new options in agonist
therapy. Specifically, the Drug Addiction Treatment Act
of 2000 allows qualified physicians (those with 8 hours
of opioid-dependence treatment training) to request a
waiver to prescribe opioid-agonist medications with
Food and Drug Administration (FDA) approval. In
2002, the FDA approved two forms of buprenorphine
(a partial opioid agonist)—Subutex ® (buprenorphine
alone) and Suboxone ® (buprenorphine and naloxone).
The buprenorphine/naloxone (buprenorphine) combin-
ation is designed to reduce abuse potential and is
the medication typically used in primary care settings.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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methadone maintenance [7] and buprenorphine [8] for
long-term pharmacotherapy to treat opioid dependence.
A review of the literature indicates that while metha-
done maintenance may be slightly more effective than
buprenorphine maintenance, buprenorphine may re-
duce mortality and has the added advantage that the
therapy can be managed in primary care settings [3].
Expansion of access to buprenorphine in general med-
ical systems could extend agonist therapy to many un-
treated opioid-dependent persons who either do not
have access to a methadone clinic or who do not want
the burden of daily medication visits. In addition,
expanding access may improve the quality of care for
opioid-dependent individuals, because physicians in
general medical settings may identify and manage co-
occurring health consequences of opioid dependence as
part of monitoring the agonist pharmacotherapy [9,10].
Most commercial health systems, however, have little ex-
perience with providing opioid-agonist therapy [11]. Infor-
mation on the cost of alternative treatments is particularly
salient, as health systems face increased competition, pres-
sure to reduce costs, and increasing requirements to
provide comprehensive mental health and addiction treat-
ments [12,13]. Health systems need to understand the dir-
ect cost of the intervention, as well as its impact on other
health care costs. While the direct cost of buprenorphine is
significantly higher than the cost of methadone [14,15], it is
less clear how buprenorphine affects other health care
spending. Office-based buprenorphine treatment, for ex-
ample, may decrease the need for emergency department
visits, increase appropriate contact with primary care and,
as a result, increase identification of and treatment for co-
morbid conditions [16], which might be more costly ini-
tially, but might also improve health outcomes and reduce
long-term costs.
Research on patterns of the cost and cost-effectiveness
of buprenorphine compared to alternative therapies has
been mixed. Studies in publicly funded health systems
(Veterans Administration, Medicaid) reported lower
costs for buprenorphine patients compared to metha-
done patients [14,17]; commercial health systems, how-
ever, might experience different costs. Buprenorphine
appears to be cost-effective under certain scenarios
[18,19], yet other studies suggest that methadone main-
tenance is more cost-effective [15,20,21]. None of these
studies examined the cost or cost-effectiveness of
buprenorphine in a commercially insured population.
In addition, prior studies have not assessed the incre-
mental cost of buprenorphine in combination with
counseling, compared to counseling only (without
opioid-replacement medication), which is the primary
form of care for substance abuse in many private com-
mercial health systems.The focus of this paper is to provide information for
health system decisionmakers about the impact of bupre-
norphine treatment for opioid dependence in commercial
health systems. We assessed the utilization and health care
costs for opioid-dependent patients and compared pa-
tients receiving buprenorphine plus counseling from ad-
diction medicine providers to opioid-dependent patients
receiving counseling only, and to opioid-dependent pa-
tients receiving little or no addiction treatment. We ad-
dress two research questions: 1) Are total health system
costs different for persons treated with buprenorphine
plus counseling, compared with those who are treated
with counseling only and those receiving little or no ad-
diction treatment? 2) Are patterns of addiction treatment
and other medical care services different for persons
treated with buprenorphine plus counseling, compared
with those who are treated with counseling only or those
with little or no addiction treatment?Methods
We conducted a retrospective cohort study using data from
two large, nonprofit, integrated health systems that provide
addiction medicine treatment and comprehensive medical
care. Patients were categorized into one of three treatment
groups: buprenorphine plus counseling, counseling only
(two or more counseling sessions and no medication), and
little or no addiction treatment (one or fewer counseling
sessions and no medication). We used multivariate analyses
to assess health care utilization patterns and total costs for
2007–2008. Both health systems had implemented bupre-
norphine treatment and had stable patient populations dur-
ing this time period. Propensity scores helped control for
differences in patient characteristics that could be related to
type of treatment received.Addiction medicine services: health system A
In Health System A, persons presenting with opioid-
dependence diagnoses receive a medical assessment to
determine the level of care needed. Depending on client
preference and the medical provider’s assessment, the
patient may or may not receive agonist medication. All
patients, whether treated with agonist therapy or not,
are strongly encouraged to attend addiction counseling.
Patients who refuse addiction counseling may be dis-
continued from agonist medication. Addiction medicine
services include residential treatment, specialty out-
patient groups for persons with opioid dependence,
general outpatient counseling groups, and individual
therapy. Patients receiving buprenorphine participate in
case management and sign a treatment agreement
that states the expectations for continued buprenor-
phine care. Frequent, random, urine drug screens are
required.
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In Health System B, patients with chemical dependency,
including opioid dependence, receive an individualized
clinical assessment. Outpatient, day-hospital, or residen-
tial treatment is provided. Day treatment is more inten-
sive, generally including four times the amount of each
service as outpatient treatment, although the content is
the same. Patients using buprenorphine are integrated
with other patients in the group-based program and also
attend buprenorphine-specific groups. Patients are ex-
pected to attend 12-step meetings off-site. Patients re-
ceive frequent, random breathalyzer and urine drug
screens throughout their treatment.
Study sample
We identified individuals with two or more health sys-
tem encounters with diagnoses of opioid dependence,
using clinical and administrative data for the calendar
years 2007–2008. All identified members had at least
one month of health system eligibility in the year prior
to the study. We included all service use and related
cost data for services paid for by the health systems, in-
cluding care provided directly through the health sys-
tems and claims for services provided outside of the
health systems. We examined the use and cost of addic-
tion treatment (including inpatient treatment, residen-
tial treatment, and outpatient counseling) and other
medical services (primary care, emergency services,
mental health services, and other non-addiction medical
visits) during the study period. Both inpatient and out-
patient costs outside the health system were obtained
from outside claims and referral systems and were based
on the amount the health system actually paid to the
vendor, versus the amount billed to the vendor. Pre-
scription costs were obtained from internal data from
the health systems and approximate retail costs (acqui-
sition cost, plus dispensing fee). We used the Consumer
Price Index to adjust for inflation.
To control for possible differences in health conditions
related to type of treatment received, we categorized all
diagnoses for each member in the year prior to the opi-
oid diagnosis using a disease classification system (CBC)
[22], updated for ICD-9-CM codes. This system orga-
nizes health problems into groups that share important
dimensions, including severity, etiology, duration, and
anticipated use of medical resources. The system has 19
primary categories (e.g., chronic disease, serious; micro-
organism, less serious). All disease codes and V codes
are assigned to a single appropriate category, simplifying
diagnosis-related analyses, and then coded 0 for none in
the category or 1 for at least one event in the category.
Institutional Review Boards (IRBs) for the two health
systems reviewed and approved the study protocol.
Oregon Health & Science University’s review boardceded oversight of the study to the two health systems’
IRBs, because the study analyzed health system records.
Analysis
Multivariate analyses examined patterns of health ser-
vice use and cost by comparing the different treatment
modality groups. Because treatment assignment was ob-
served (and not randomized), we created propensity
scores using multinomial regression, predicting type of
treatment received (with buprenorphine as the reference
group) to help control for systematic differences in the
treatment modality groups. The propensity score model
included the 19 CBC scores in the prior year, number of
opioid diagnoses in the prior year, six variables for health
care utilization in the prior year (detoxification stays, in-
patient stays, primary care visits, emergency room visits,
mental health visits, and other/specialty visits), number
of days in the prior year on buprenorphine, the Charlson
comorbidity score for the year prior, months of health
system eligibility in the year prior, age, gender, and site.
Since we used multinomial regression with three levels
of the outcome variable, each person received three pro-
pensity scores. To examine the fit of the model, each
person was classified into the group associated with the
highest propensity score and computed percent correct
classification. To examine the balance of propensity
scores, we computed the median standardized difference
across the 42 covariates [23]. We were interested in the
impact on costs and utilization from a health plan per-
spective; therefore, we did not use propensity score
matching, as that would have limited the generalizability
to only those cases that could be matched. Because each
person received three propensity scores, we did not use
inverse probability weighting and instead, included the
propensity scores as covariates in the main analyses (the
propensity scores sum to 1.0, so we included two of the
three propensity scores). The same individuals could ap-
pear in more than one year; therefore, we used general-
ized estimating equations (GEE) to model the covariance
structure and test for differences in utilization among
the study groups, controlling for propensity of type of
treatment received, site, age, gender, and months of eligi-
bility in the health system. We used Poisson and nega-
tive binomial models with a log-link function to examine
health care utilization variables. Our analyses of in-
patient detoxification used only those patients who were
not on Medicaid (n = 5757), because inpatient detoxifica-
tion services were not part of the Medicaid-contracted
services with the health systems. All other utilization
analyses included all patients (N = 6040) and Medicaid
status as an additional covariate. A generalized linear
model with gamma distribution, log-link function, and
robust standard errors was used to analyze total costs.
Cost analyses were adjusted to 2008 dollars. Total costs
Table 2 Mean (SD) characteristics and utilization in the
year prior to study by treatment group
Counseling Little or no addiction Buprenorphine
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patient, primary care, all other specialty care medical
services (e.g., mental health care), and pharmaceuticals.only treatment plus counseling
Age 40.95 (13.10) 48.65 (15.14) 36.02 (12.46)
Female (%) 51% 62% 43%
Number of
opioid dx









16.15 (36.67) 1.96 (11.60) 18.31 (40.52)
Days on
buprenorphine
2.81 (21.87) 1.55 (16.65) 72.70 (126.86)Results
Table 1 summarizes characteristics of the population sam-
ples from the two health plans; 52 percent of the patients
were female, and the mean age was 42 years. Overall, the
three patient groups were relatively similar in total numbers
and percentage: 30 percent with little or no addiction treat-
ment, 32 percent with buprenorphine plus counseling, and
38 percent with counseling only. The two health plans,
however, differed in the use of buprenorphine; in Health
Plan A, 45 percent of the opioid-dependent patients re-
ceived buprenorphine, versus 27 percent in Health Plan B.Charlson
comorbidity
score
0.32 (0.59) 0.67 (0.99) 0.18 (0.46)Propensity model
The model correctly predicted group membership for
60.3 percent of the cases, where 33.3 percent correct
classification would be expected by chance alone. Cor-
rect classification was similar for the three groups (coun-
seling only – 61.0%, little or no treatment – 62.4%,
buprenorphine plus counseling – 57.7%). The standard-
ized median difference (a measure of balance of the pre-
dictors across the groups) for the two propensity scores
were .18 and .35. Values < .25 were considered an accept-
able fit [23]. This is particularly important when the pro-
pensity scores are used for matching or stratification.
However, the propensity scores were not used for
matching or stratification in this study, but were in-
cluded as covariates in the main analysis, which helped
to mitigate any lack of balance in the second propensity
score. Age, gender, comorbidity, and prior health care
were the strongest predictors in the model. Table 2 sum-
marizes the three groups on these variables. In general,
the buprenorphine group was younger, less likely to be fe-
male, had fewer comorbidities, had more previous diagno-
ses of opioid dependency, had more addiction medicine







n = 1836 n = 4204 N = 6040
Age in years, Mean (SD) 39 (15) 43 (14) 42 (14)
Gender,% female 50% 52% 52%
Counseling only, n 499 1781 2280
Little or no addiction treatment, n 513 1301 1814
Buprenorphine plus counseling, n 824 1122 1946Costs
Table 3 presents the adjusted mean total health care
costs per person, per year, by group. Patients receiving
buprenorphine plus counseling had significantly lower
total health care costs ($13,578; 95% CI: $13,364–
$13,791) than those with little or no treatment ($31,035;
95% CI: $30,433–$31,637; p < .001). Total health care
costs did not differ significantly between those receiving
buprenorphine plus counseling and those with counsel-
ing only ($17,017; 95% CI: $16,751–$17,285); p = .569).
Patterns of service use
Table 4 presents the patterns of health care utilization by
treatment group. In comparison to the buprenorphine
plus counseling group, the group with little or no addic-
tion treatment had significantly greater use of primary
care (z = 4.33, p < .001), other medical visits (z = 3.24,
p = .001), and emergency services (z = 2.33, p = .020). Pa-
tients with counseling only (compared to patients with
buprenorphine plus counseling) used less inpatient detoxi-
fication (z = −8.57, p <. 001), and had significantly more
PC visits (z = 3.41, p = .001), other medical visits (z = 2.84,
p = .005), and mental health visits (z = 3.09, p = .002). The
counseling only and buprenorphine plus counseling
groups did not differ significantly on use of residential
treatment or emergency services.
Discussion
Access to buprenorphine treatment for opioid depend-
ence has increased and is likely to continue to increase
because the Mental Health Parity and Addiction Equity
Act and the Affordable Care Act enhance health insur-
ance coverage for mental health and addiction treatment
services. Commercial health systems caring for persons
Table 3 Adjusted mean annual cost 2008 U.S. dollars










Costs are adjusted for age, gender, months of eligibility in the health system,
site, and propensity of type of treatment received.
t – Not significantly different from buprenorphine plus counseling at the
.05 level.
**Significantly different from buprenorphine plus counseling at p < .001.
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vices to promote the best possible outcomes within
highly constrained budgets. Results from this study sug-
gest that health system costs for persons treated with
buprenorphine plus counseling were similar to health
system costs for persons treated with counseling only,
and about $17,000 per year less than the health system
costs for patients with little or no addiction treatment. The
availability of generic buprenorphine/naloxone, moreover,
should reduce costs for the buprenorphine plus counseling
group in the future. Patients with little or no addiction
treatment had significantly greater use of medical services;
notably, emergency services. Opioid-dependent patients
not engaged in addiction treatment may continue to have
significant health consequences related to opioid use. In
contrast, the patients with buprenorphine plus counseling
and counseling only had similar lower levels of emergency
services, suggesting that their addiction treatment reduced
the need for crisis care. Patients with counseling only used
more primary care services, mental health services, and
other medical visits than patients with buprenorphine plus
counseling. Reductions in the use of primary and other
medical care services amongst buprenorphine plus counsel-
ing patients may reflect additional care coordination or ad-
vice received during medication management visits.
The two health systems participating in this study
both provide comprehensive health care services toTable 4 Mean health care utilization (SE) by treatment group










Estimates are adjusted for age, gender, months of eligibility in the health system, M
t – Not significantly different from buprenorphine plus counseling at the .05 level.
*Significantly different from buprenorphine plus counseling at p < .05.commercially insured populations, much of which are dir-
ectly provided by the health systems. At the time of the
study, both systems had set up infrastructure to support
buprenorphine services (physician and counselor training,
and pharmacy access) and had increased the number and
percentage of patients receiving buprenorphine [24]. How-
ever, they were both relatively new to managing buprenor-
phine treatment. System B, in particular, had a more
complex system of providers across a larger geographic
area. Uptake and implementation was slower in System B,
and System B had less prior experience with opioid-agonist
therapy. The health system costs associated with buprenor-
phine treatment may change over time, as health systems
become more experienced and efficient at providing
opioid-agonist therapy.
Buprenorphine treatment provides clinical outcomes
that are similar or better than other addiction medicine
treatment approaches for persons with opioid depend-
ence. Most prior studies, however, focused on the use of
buprenorphine in publicly insured populations. Results
of this study provide evidence that buprenorphine treat-
ment can be provided at a cost similar to abstinence-
based counseling in commercial health systems. In
addition, buprenorphine may have three advantages
compared to alternative treatments. Convenience is a
major consideration; patients treated with buprenor-
phine are not required to go to a specialized clinic every
day to receive medication, and general medical offices
tend to be closer to patient’s homes, with lower patient
travel costs. Second, patients often prefer the medical
office treatment environment because of their familiar-
ity with providers and facilities and their trust in pro-
viders to help them address medical conditions related
to opioid use. Finally, patients report that medical
settings provide a better environment to maintain sobri-
ety and avoid others who are current users of illicit
drugs [24].
Limitations
Interpretation of our results should be considered in
light of several limitations. The current study used datatays PC visits ER visits MH visits Other visits
7.92* 1.25t 3.30* 5.81*
(.06) (.06) (.09) (.04)
7.87* 1.45* 2.94t 6.22*
(.04) (.06) (.12) (.05)
6.15 1.10 2.33 4.97
(.03) (.08) (.09) (.04)
edicaid status, site, and propensity of type of treatment received.
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prehensive and detailed electronic medical records. Al-
though the diagnostic data is very likely to be accurate,
we were not able to group people by how long they had
been in treatment for opioid dependence, which could
influence health care costs. Our retrospective cohort
analysis did not randomize participants to treatment
modality. We addressed this issue by using propensity
scores obtained from a model that included prior health
care utilization and other important factors to adjust for
differences between groups related to selection into spe-
cific treatment modalities. Although this approach could
help to control for observable differences, it did not ad-
dress differences from unobservable factors and there-
fore, causal inferences cannot be drawn. The measure of
balance of the predictors across groups met the pre-
ferred level (< .25 for goodness of fit [23]) for one of the
propensity scores, but was .35 for the second propensity
score. However, this measure is most important for
matching and stratification and in this study, the pro-
pensity scores were used as covariates helping to miti-
gate any lack of balance in this score. An additional
concern with use of propensity scores for covariate ad-
justment is that it requires an assumption that outcomes
of the regression are correctly specified. These limita-
tions may lead to a bias in the magnitude of effects de-
tected, although this issue is less of a concern in the
context of larger samples (e.g., sample size in the 1000s)
[25,26]. Both integrated health systems are located in
the Western United States, so results may not be
generalizable to other populations or geographic regions.
On the other hand, the analysis included all patients
with opioid-dependence diagnoses enrolled in two large
integrated health systems, so our results are likely to
represent what these types of private, integrated, health
systems experience in practice. This study focused on
providing information that could be useful to health sys-
tem decisionmakers. However, a health system perspec-
tive does not include some important nonhealth social
costs. For example, criminal justice costs might be re-
duced by the increased use of buprenorphine treatment.Conclusions
Results of this study suggest that buprenorphine can be
offered in integrated health systems to commercially in-
sured patients at total health care costs that are similar
to those seen with abstinence-based counseling pro-
grams. Patients treated with buprenorphine plus coun-
seling had reduced use of general medical services
compared to those treated with alternative approaches.
Future research needs to examine the long-term costs
related to alternative treatments for opioid dependence,
both from the health system and the patient perspective.Competing interests
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